Afya-YDUQS Mega-Merger Would Build a Brazilian Education Giant — But Can Shareholders Stomach Leaving Nasdaq Behind?

Shares of Afya jumped 7.6% to $13.15 as investors continued digesting the blockbuster agreement to merge Brazil's leading medical-school operator with YDUQS, one of the country's largest for-profit university groups. The deal, if completed, would create a combined platform with roughly 1.6 million students and R$9.4 billion in combined revenue — but it also means Afya disappears from Nasdaq entirely.

• A Voting Pact Locks In the Deal's Biggest Backers. The agreement aligns key investors, including the Zaher and Esteves family holdings and Bertelsmann, to back the merger.

Controlling shareholders agreed to support the transaction at required meetings and accepted interim limits on share transfers and votes against actions that could derail the deal before closing. This matters because it effectively removes the risk that insiders could torpedo the vote. Break fees of BRL 100 million apply to a breaching YDUQS shareholder, BRL 100 million for the Esteves family, and a scaled BRL 325 million for Bertelsmann — real financial penalties that signal commitment.

• Afya Shareholders Get the Bigger Slice, But Lose Their U.S. Listing. Afya shareholders are set to hold 69% of the combined company on a fully diluted basis, at an exchange ratio of 6.41 new YDUQS shares per Afya share.

Afya's Nasdaq-listed Class A shares are expected to be delisted; the combined company would remain listed only on B3. For U.S.-based investors who can't or won't hold Brazilian-listed stock, this is a forced exit — potentially depressing Afya's price until closing.

• Medical Education Becomes the Economic Engine. The new group will have approximately 38,000 undergraduate medical students and 5,888 authorized annual medical-school seats. Medical seats are the most profitable segment in Brazilian private higher education, and Bertelsmann, with about 47% of the capital, will appoint a majority of the board.

Afya's current CEO, Virgilio Gibbon, will lead the combined group. In practice, this is Afya absorbing YDUQS's scale while keeping operational control.

• The Clock Is Long and the Hurdles Are Real. Closing is targeted by March 31, 2028, with break-up fees including BRL 325 million pre-shareholder meetings or BRL 650 million post-approval.

Both companies need shareholder approval, Brazil's antitrust authority CADE has to clear the combination, and certain third parties must consent. At a current market cap near $1.2 billion and a P/E of roughly 8x, Afya trades cheaply — but the 18-month regulatory timeline leaves plenty of room for deal risk to weigh on the stock.